Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
belotecan + ifosfamide
- Development stage
- Phase 2
- Lead developer
- Chong Kun Dang Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Belotecan + ifosfamide is an investigational combination chemotherapy regimen consisting of belotecan, a camptothecin analog and topoisomerase I inhibitor, and ifosfamide, an alkylating agent. This combination has been studied in clinical trials for the treatment of small cell lung cancer (SCLC). Belotecan inhibits DNA topoisomerase I, leading to DNA damage and apoptosis in rapidly dividing tumor cells. Ifosfamide acts as a cytotoxic alkylating agent that crosslinks DNA strands, thereby inhibiting DNA replication and transcription. The combination aims to enhance antitumor efficacy by targeting cancer cells through complementary mechanisms[1][2].
02
Targets
DNATOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on belotecan + ifosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on belotecan + ifosfamide.